ASHA 093
Alternative Names: ASHA-093Latest Information Update: 31 Mar 2025
At a glance
- Originator Asha Therapeutics
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Dynamin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Feb 2025 Preclinical trials in Cardiovascular disorders in USA (unspecified route) (Asha Therapeutics Pipeline, February 2025 )
- 28 Feb 2025 Preclinical trials in Metabolic disorders in USA (unspecified route) (Asha Therapeutics Pipeline, February 2025)